AI Nose study will test breathprints for emergency diagnosis

The Register reported that Ainos, an AI and biotech company, is working with National Taiwan University on a year-long study starting in July to test whether its Smell AI platform can help diagnose patients by analyzing volatile organic compounds in exhaled breath. The study will focus on people with dyspnea, a common emergency-department symptom that can reflect conditions such as acute COPD exacerbation or acute decompensated heart failure. Ainos says its AI Nose module uses MEMS sensors and a proprietary Smell Language Model to classify scent patterns.

Key details: Published June 18, 2026 at 13:45 UTC, The research program is scheduled to start in July, The study targets patients presenting with dyspnea, The platform analyzes VOC-based breathprints using MEMS sensors and a Smell Language Model.

Why it matters: Healthcare AI is not only chatbots and image models; sensor-plus-model systems like breath analysis could change triage if they survive clinical validation.